knowledge -WSS

knowledge

author：explore 2025-10-01 15:27:53 - browse：884

Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Federal weight loss drug coverage is 30 years out of date

WSS

Meta's Zuckerberg and Chan on track to put $50 billion into science

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Chimpanzees, like humans and whales, get menopause: Study

The pink breast cancer awareness ribbon needs a redesign

Testing for cancer recurrence creates a new limbo for patients

Feng Zhang CRISPR delivery startup lays off quarter of staff

leisure time

knowledge

hotspot

Peter Hotez and the public health issue of online harassment

Readout Newsletter: New research from Sanofi, Regeneron, etc.

State Dept. review finds Biden bears some blame for Afghanistan failures

Meta's Zuckerberg and Chan on track to put $50 billion into science

Walensky prepares to leave CDC — and Congress — behind

Diversifying clinical trials isn't enough to close racial gaps: study

After affirmative action ruling, medical educators look to 'holistic review'

Diversifying clinical trials isn't enough to close racial gaps: study

Guidelines to prevent youth baseball injuries need more muscle

The biotech scorecard for Q1: 17 stock

entertainment

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The pink breast cancer awareness ribbon needs a redesign

Readout Newsletter: XBI biotech index, Akero Therapeutics

J&J to buy cancer drug developer Ambrx Biopharma

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

focus

entertainment

Wikipedia

explore